74 related articles for article (PubMed ID: 24788408)
1. Effect of verapamil on the pharmacokinetics of pasireotide in healthy volunteers.
Kornberger R; Ting LS; Tripathi AP; Rodrigues H; Nesheiwat D; Passos VQ; Hu K
J Clin Pharmacol; 2014 Nov; 54(11):1263-71. PubMed ID: 24788408
[TBL] [Abstract][Full Text] [Related]
2. Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.
Beglinger C; Hu K; Wang Y; Bouillaud E; Darstein C; Wang Y; Mohideen P
Endocrine; 2012 Oct; 42(2):366-74. PubMed ID: 22527887
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study.
Chen X; Shen G; Jiang J; Liu H; Hu K; Darstein C; Lasher J; Hu P
Clin Ther; 2014 Aug; 36(8):1196-210. PubMed ID: 25012727
[TBL] [Abstract][Full Text] [Related]
4. Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.
Petersenn S; Hu K; Maldonado M; Zhang Y; Lasher J; Bouillaud E; Wang Y; Mann K; Unger N
Clin Ther; 2012 Mar; 34(3):677-88. PubMed ID: 22364824
[TBL] [Abstract][Full Text] [Related]
5. Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.
Petersenn S; Unger N; Hu K; Weisshaar B; Zhang Y; Bouillaud E; Reséndiz KH; Wang Y; Mann K
J Clin Pharmacol; 2012 Jul; 52(7):1017-27. PubMed ID: 21673137
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the absorption, metabolism and excretion of [¹⁴C]pasireotide in healthy volunteers using accelerator mass spectrometry.
Lin TH; Hu K; Flarakos J; Sharr-McMahon M; Mangold JB; He H; Wang Y
Cancer Chemother Pharmacol; 2013 Jul; 72(1):181-8. PubMed ID: 23680921
[TBL] [Abstract][Full Text] [Related]
7. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers.
Golor G; Hu K; Ruffin M; Buchelt A; Bouillaud E; Wang Y; Maldonado M
Drug Des Devel Ther; 2012; 6():71-9. PubMed ID: 22573933
[TBL] [Abstract][Full Text] [Related]
8. Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study.
Horsmans Y; Hu K; Ruffin M; Wang Y; Song D; Bouillaud E; Wang Y; Mazur D; Botha FP; Heuman DM
J Clin Pharmacol; 2012 Apr; 52(4):552-8. PubMed ID: 22282526
[TBL] [Abstract][Full Text] [Related]
9. Clinically important interaction between tedisamil and verapamil.
van Haarst AD; Dijkmans AC; Weimann HJ; Kemme MJ; Bosch JJ; Schoemaker RC; Cohen AF; Burggraaf J
J Clin Pharmacol; 2009 May; 49(5):560-7. PubMed ID: 19299533
[TBL] [Abstract][Full Text] [Related]
10. Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants.
Rebello S; Leon S; Hariry S; Dahlke M; Jarugula V
J Clin Pharmacol; 2011 Feb; 51(2):218-28. PubMed ID: 20413453
[TBL] [Abstract][Full Text] [Related]
11. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil.
Krecic-Shepard ME; Barnas CR; Slimko J; Schwartz JB
Clin Pharmacol Ther; 2000 Sep; 68(3):286-92. PubMed ID: 11014410
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetic and electocardiographic study of oral verapamil sustained-release tablet in 10 Chinese volunteers].
Liu XD; Xie L; Wang J; Zhou YS; Wang Z; Liu GQ
Yao Xue Xue Bao; 1996; 31(7):487-91. PubMed ID: 9772689
[TBL] [Abstract][Full Text] [Related]
13. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers.
Henry RR; Ciaraldi TP; Armstrong D; Burke P; Ligueros-Saylan M; Mudaliar S
J Clin Endocrinol Metab; 2013 Aug; 98(8):3446-53. PubMed ID: 23733372
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study.
Dietrich H; Hu K; Ruffin M; Song D; Bouillaud E; Wang Y; Hasskarl J
Eur J Endocrinol; 2012 May; 166(5):821-8. PubMed ID: 22383336
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Verapamil, a P-Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK Inhibitor.
Zhu T; Howieson C; Wojtkowski T; Garg JP; Han D; Fisniku O; Keirns J
Clin Pharmacol Drug Dev; 2017 Nov; 6(6):548-555. PubMed ID: 28301084
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Safety of Long-Acting Release Formulations of Pasireotide (SOM230) in a Male Population Who Are Hyperendemic Hepatitis B/C and Chronic Kidney Disease: An Open-Label, Phase I Study.
Huang CJ; Lu CH; Shih KC
Eur J Drug Metab Pharmacokinet; 2023 Nov; 48(6):665-674. PubMed ID: 37751056
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.
Petersenn S; Bollerslev J; Arafat AM; Schopohl J; Serri O; Katznelson L; Lasher J; Hughes G; Hu K; Shen G; Reséndiz KH; Giannone V; Beckers A
J Clin Pharmacol; 2014 Nov; 54(11):1308-17. PubMed ID: 24800725
[TBL] [Abstract][Full Text] [Related]
18. Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking.
Kang D; Verotta D; Krecic-Shepard ME; Modi NB; Gupta SK; Schwartz JB
Clin Pharmacol Ther; 2003 Jan; 73(1):31-40. PubMed ID: 12545141
[TBL] [Abstract][Full Text] [Related]
19. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.
Macha S; Sennewald R; Rose P; Schoene K; Pinnetti S; Woerle HJ; Broedl UC
Clin Ther; 2013 Mar; 35(3):226-35. PubMed ID: 23497760
[TBL] [Abstract][Full Text] [Related]
20. Dose proportionality of pharmacokinetics with a cr-verapamil formulation.
Mulligan S; Devane J; Martin M
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():304-11. PubMed ID: 1820898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
